α1-antitrypsin (A1AT) and C1 esterase inhibitor (C1INH) are two examples of human plasma proteins that possess homogeneous and distinct glycoprofiles and are used as plasma-derived augmentation therapy to treat α1-antitrypsin deficiency (AATD) or hereditary angioedema (HAE-C1INH), respectively [68]. This evidence concerns the gene SERPING1 and hereditary angioedema.